Zacks Research Comments on Danaher's Q1 Earnings (NYSE:DHR)

Danaher Co. (NYSE:DHR - Free Report) - Investment analysts at Zacks Research dropped their Q1 2025 EPS estimates for shares of Danaher in a report released on Tuesday, March 25th. Zacks Research analyst R. Department now forecasts that the conglomerate will post earnings of $1.61 per share for the quarter, down from their prior estimate of $1.62. The consensus estimate for Danaher's current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Danaher's Q2 2025 earnings at $1.76 EPS, Q3 2025 earnings at $1.85 EPS, FY2025 earnings at $7.59 EPS, Q1 2026 earnings at $1.84 EPS and FY2026 earnings at $8.50 EPS.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the firm earned $2.09 earnings per share.

A number of other equities research analysts have also commented on the company. Scotiabank started coverage on Danaher in a research report on Monday, December 23rd. They issued a "sector perform" rating and a $265.00 price target for the company. StockNews.com cut shares of Danaher from a "buy" rating to a "hold" rating in a report on Saturday, December 14th. Jefferies Financial Group dropped their target price on shares of Danaher from $285.00 to $260.00 and set a "buy" rating on the stock in a research report on Wednesday, January 29th. The Goldman Sachs Group raised Danaher from a "neutral" rating to a "buy" rating and set a $260.00 target price for the company in a report on Friday, March 21st. Finally, Bank of America upgraded Danaher from a "neutral" rating to a "buy" rating and set a $290.00 price objective for the company in a research note on Friday, December 13th. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and a consensus price target of $278.24.

Remove Ads

Danaher Stock Down 1.5 %

DHR traded down $3.11 during midday trading on Thursday, reaching $202.75. 970,368 shares of the company were exchanged, compared to its average volume of 3,177,881. Danaher has a one year low of $196.80 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The company's fifty day moving average price is $214.57 and its 200 day moving average price is $236.39. The company has a market cap of $144.90 billion, a price-to-earnings ratio of 38.44, a price-to-earnings-growth ratio of 2.66 and a beta of 0.82.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.32 dividend. The ex-dividend date is Friday, March 28th. This represents a $1.28 annualized dividend and a dividend yield of 0.63%. This is a boost from Danaher's previous quarterly dividend of $0.27. Danaher's dividend payout ratio is presently 24.24%.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the company's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Danaher

Institutional investors and hedge funds have recently bought and sold shares of the stock. Norges Bank purchased a new position in Danaher in the fourth quarter worth $2,130,740,000. Raymond James Financial Inc. bought a new position in shares of Danaher during the 4th quarter valued at about $391,172,000. Two Sigma Advisers LP lifted its position in Danaher by 4,248.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after buying an additional 1,601,800 shares during the last quarter. Capital World Investors boosted its stake in Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock worth $1,460,215,000 after buying an additional 1,566,658 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its position in Danaher by 460.6% during the fourth quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock valued at $309,558,000 after acquiring an additional 1,107,998 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.